Nutriband Inc. reported full-year 2025 revenue of US$2.14 million, an increase of 2.6% from FY 2024. The company also reported a net loss for the period, a common characteristic of early-stage pharmaceutical development companies.
In a letter to shareholders, CEO Gareth Sheridan highlighted the successful raise of $8.4 million USD in April 2024 through a non-brokered private placement, primarily from existing shareholders. This financing strengthened the company's financial foundation for its AVERSA product research and development.
The company confirmed significant strides in the development and scale-up of the manufacturing process for AVERSA™ Fentanyl, and the formalization of its exclusive product development partnership with Kindeva Drug Delivery. Nutriband also expanded its worldwide intellectual property portfolio with approvals in China, Hong Kong, Macao, and a new US patent allowance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.